VRM
REGN icon

Vectors Research Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Vectors Research Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,025
Closed -$987K – 135
2024
Q1 		$987K Sell
1,025
-39
-4% -$37.1K 0.28% 80
2023
Q4 		$935K Sell
1,064
-12
-1% -$9.88K 0.26% 79
2023
Q3 		$849K Sell
1,076
-13
-1% -$10.2K 0.28% 75
2023
Q2 		$782K Sell
1,089
-73
-6% -$56.3K 0.22% 85
2023
Q1 		$955K Sell
1,162
-8
-0.7% -$6.03K 0.25% 79
2022
Q4 		$844K Sell
1,170
-41
-3% -$30.3K 0.22% 84
2022
Q3 		$834K Sell
1,211
-18
-1% -$11.3K 0.24% 79
2022
Q2 		$726K Sell
1,229
-38
-3% -$24.7K 0.18% 92
2022
Q1 		$885K Sell
1,267
-20
-2% -$12.7K 0.19% 90
2021
Q4 		$813K Buy
1,287
+39
+3% +$24K 0.17% 99
2021
Q3 		$755K Buy
1,248
+36
+3% +$22.3K 0.18% 99
2021
Q2 		$677K Buy
1,212
+37
+3% +$18.7K 0.17% 103
2021
Q1 		$556K Buy
+1,175
New +$572K 0.15% 107
2020
Q3 		– Sell
-25
Closed -$16K – 454
2020
Q2 		$16K Hold
25
– – 0.01% 253
2020
Q1 		$12K Hold
25
– – 0.01% 282
2019
Q4 		$9K Buy
+25
New +$8.41K ﹤0.01% 365

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vectors Research Management's REGN Position: Q2 2024 in Review

Vectors Research Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 1,025 shares — an estimated $987K sold.

Vectors Research Management first reported a position in REGN in Q4 2019 and held it in 16 quarters. The position peaked at $987K in Q1 2024. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

  • Vectors Research Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Vectors Research Management sold 1,025 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $987K.
  • Vectors Research Management first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 16 quarters.
  • Vectors Research Management's Regeneron Pharmaceuticals position peaked at $987K in Q1 2024.
  • 1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Vectors Research Management's 13F filing for Q2 2024, filed 9 Aug 2024.